Researchers from the University of Washington and Stanford University have used bioinformatics to develop proteins that bound to specific forms of the interleukin-2 (IL-2) receptor, but otherwise had no structural similarity to IL-2.
Researchers have identified a single nucleotide polymorphism (SNP) that affected whether the diabetes drug Avandia (rosiglitazone, GlaxoSmithKline plc) would cause a rise in cholesterol levels.
Researchers at the University of Washington have developed a "nanoscavenger" that was able to protect mice from the consequences of organophosphorus (OP) compounds.
"Let me tell you about the very rich. They are different from you and me," F. Scott Fitzgerald wrote in his short story "All the Sad Young Men," to which Ernest Hemingway had a character in "The Snows of Kilimanjaro" reply "Yes, they have more money."
In terms of biomedical research progress, 2018 was a quieter year than some of its predecessors. The biggest news of the year may lie in changes in the way research – a deeply human endeavor – is conducted, setting the stage for the breakthroughs of tomorrow.
Researchers from The Jackson Laboratory have developed Alzheimer's disease (AD) model mice that were identical in the known AD risk gene they carried, but differed in the rest of their genome. The team hopes to use the animals to understand genetic factors that interact with known familial risk genes.
